Concepedia

David Eiznhamer

DE

Statistics

Publications

16

Citations

1.1K

H-Index

13

Active since

1994

Affiliations

Eon Corporation (United States)(Current)

Sarah Cannon

Dana-Farber Cancer Institute

University of Minnesota

Loyola University Chicago

David Eiznhamer is an author at Eon Corporation (United States) specializing in pharmacology, medicine, and oxidative stress.

Top concepts

Publications per year

1994–2021

16

Publications

16

Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study

Corey Cutler, Stephanie J. Lee, Sally Arai et al. · Blood · 2021 · 295 citations · Full text

ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease

Madan Jagasia, Aleksandr Lazaryan, Carlos Bachier et al. · Journal of Clinical Oncology · 2021 · 174 citations · Full text

Betulinic acid: a promising anticancer candidate.

David Eiznhamer, Ze‐Qi Xu · PubMed · 2004 · 121 citations

, , +14

Mucosal reactive oxygen species production in oesophagitis and Barrett's oesophagus.

Mojtaba Olyaee, Stephen J. Sontag, Wisal Salman et al. · Gut · 1995 · 102 citations · Full text

, , +13

Safety and Pharmacokinetics of Single Doses of (+)-Calanolide A, a Novel, Naturally Occurring Nonnucleoside Reverse Transcriptase Inhibitor, in Healthy, Human Immunodeficiency Virus-Negative Human Subjects

Terri Creagh, Jon Ruckle, Dwain T. Tolbert et al. · Antimicrobial Agents and Chemotherapy · 2001 · 94 citations · Full text

1–5 of 16